Beacon Financial Advisory LLC Has $347,000 Stock Holdings in Abbott Laboratories $ABT

Beacon Financial Advisory LLC lifted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 37.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,548 shares of the healthcare product maker’s stock after purchasing an additional 697 shares during the quarter. Beacon Financial Advisory LLC’s holdings in Abbott Laboratories were worth $347,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Hughes Financial Services LLC acquired a new position in Abbott Laboratories in the 1st quarter valued at $27,000. Abound Financial LLC acquired a new stake in shares of Abbott Laboratories during the 1st quarter valued at about $28,000. Elequin Capital LP acquired a new position in shares of Abbott Laboratories in the 1st quarter worth approximately $30,000. JCIC Asset Management Inc. bought a new position in shares of Abbott Laboratories during the first quarter valued at $32,000. Finally, Vision Financial Markets LLC acquired a new position in Abbott Laboratories in the first quarter valued at about $33,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Performance

Shares of NYSE ABT opened at $134.49 on Monday. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $234.07 billion, a P/E ratio of 16.85, a P/E/G ratio of 2.55 and a beta of 0.69. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The stock has a 50 day moving average of $131.94 and a 200-day moving average of $131.39.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting analysts’ consensus estimates of $1.26. The firm had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period in the previous year, the business posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be given a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is 29.57%.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Leerink Partnrs upgraded shares of Abbott Laboratories to a “hold” rating in a research report on Monday, June 16th. The Goldman Sachs Group lifted their price objective on shares of Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a research note on Wednesday, October 1st. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Abbott Laboratories in a research report on Saturday, September 27th. Wells Fargo & Company lowered their target price on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a report on Friday, July 18th. Finally, BTIG Research cut their price objective on shares of Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $145.39.

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.